---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-25-000008"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T03:02:56.670586+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ligand Q4 revenue up 52% to $42.8M; core adj EPS $1.27; reaffirms 2025 guidance

## Summary
- Q4 total rev $42.8M (+52% YoY); royalties $34.8M (+55%) driven by Qarziba and Filspari.
- Core adjusted net income from cont ops $25.2M ($1.27/diluted) vs $18.6M ($1.05) prior year.
- Full year adj net income $156.0M ($8.25/diluted); core adj $108.5M ($5.74/diluted).
- Reaffirms 2025 guidance: total rev $180-200M, adjusted EPS $6.00-$6.25.
- Closed $50M royalty investment in Castle Creek Biosciences for D-Fi Phase 3 study.

## SEC filing metadata
- accession: 0000886163-25-000008
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/0000886163-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/lgnd-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-25-000008
- JSON: https://secwatch.observer/filing/0000886163-25-000008.json
- Plain text: https://secwatch.observer/filing/0000886163-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.